Follow us :
日本デスク
Site en français
Conseils en Propriété Industrielle / European Patent and Trademark Attorneys
PARIS
LYON
RENNES
MONTPELLIER
GRENOBLE
TOULOUSE
MUNICH
Client Login
News
Events
In France and abroad
Legal News
Current IP News
Press Room
Press Releases
INFORMATION COVID-19
Expertise
Patents
Life Sciences and Chemistry
IT / Mechanics / Physics
Focus on our EP Practice
Unitary Patent
Trademarks & Designs
Our expertise
Contracts, IP valuation & Data
Drafting of your contracts
IP asset valuation
GDPR compliance
IP Intelligence
Patentability Study
Freedom to operate
Anticipating developments
For the last 80 years, we have been assisting our clients in protecting, developing and defending their innovations and creations.
Training
IP TRAINING
IP Academy
5-day seminar
Publications
Last Published
Current IP News
published by our IP Attorneys
Search for a publication
All our articles organised
by theme, author, IP rights
Focus on
Discover a selection of our publications arranged by topic.
IPON Newsletter
Read our latest newsletter
Team
Partners
Our team
Find your contact among our employees
REGIMBEAU's Network
Our network of International Associates and our involvement in Professional Organisations
日本デスク
Japan Desk
Careers
Join us
Discover our current employment offers and send your application
Contact us
Paris
Lyon
Rennes
Montpellier
Grenoble
Toulouse
Munich
Home
>
Publications
>
Search for a publication
>
Article
35 USC § 101: Further clarification of patent subject-matter eligibility.
35 USC § 101: Further clarification of patent subject-matter eligibility.
By Sara HAINES, US Patent Agent.
Two recently issued USPTO memorandums further clarify aspects of patent subject-matter eligibility under 35 USC § 101. The Vanda memo1 specifies methods of treatment that should be considered to be patent eligible under step 2A of the Alice/Mayo test2 thereby avoiding any further analysis under step 2B, while the Berkheimer memo3 states that examiners must provide substantiated evidence when additional claim elements are considered to represent well-understood, routine, conventional activity in support of 35 USC § 101 rejections under step 2B.
Published on: 30th Oct 2018
Patent
Patentability of Biological Material
Biomarkers
Download the article
Click here